Provention Bio Inc (NASDAQ:PRVB)
| 9.29 Delayed Data As of Nov 28 |  -0.20 / -2.11%Today’s Change | 3.19 Today|||52-Week Range 9.85 | +65.30% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $828.3M |
Company Description
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.
Contact Information
Provention Bio, Inc. 55 Broad Street Red Bank New Jersey 07701-1902 |
Employees
Shareholders
| Other institutional | 37.19% |
| Individual stakeholders | 16.25% |
| Mutual fund holders | 12.18% |
Top Executives
| Ashleigh W. Palmer | Chief Executive Officer & Director |
| Christina Yi | Chief Operating Officer |
| Thierry Chauche | Chief Financial Officer |
| Francisco Leon | Chief Scientific Officer |
| Eleanor Leni Ramos | Chief Medical Officer |
